Matinas BioPharma
MTNB
45 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
371% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 7
156% more capital invested
Capital invested by funds: $7.01M → $18M (+$10.9M)
137% more funds holding
Funds holding: 19 → 45 (+26)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.15% more ownership
Funds ownership: 0.09% → 0.23% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.57M |
| 2 |
BlackRock
New York
|
+$6.43M |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$1.88M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$691K |
| 2 |
Goldman Sachs
New York
|
-$566K |
| 3 |
SCM
Segantii Capital Management
Hong Kong
|
-$166K |
| 4 |
Morgan Stanley
New York
|
-$157K |
| 5 |
SIM
Spark Investment Management
New York
|
-$105K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
51
BlueCrest Capital Management
St Helier,
Jersey
| – | -$66K | -480 | Closed |
|
52
Barclays
London,
United Kingdom
| – | +$134 | +1 | New |
|
MTNB Hedge Fund Activity: Q2 2017 in Review
45 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2017, worth a combined $18M — up 156% from $7.01M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MTNB positions and 7 closed out — a net gain of 26 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $6.57M. The largest seller was Millennium Management, cutting an estimated $691K.
- 45 institutional investors held Matinas BioPharma (MTNB) as of Q2 2017, up from 19 in Q1 2017.
- Funds reported $18M of Matinas BioPharma stock for Q2 2017, up 156% quarter-over-quarter.
- 33 funds opened new Matinas BioPharma positions in Q2 2017 and 7 closed out, a net change of +26 holders.
- The largest Matinas BioPharma buyer in Q2 2017 was Vanguard Group, an estimated $6.57M added.
- The largest Matinas BioPharma seller in Q2 2017 was Millennium Management, an estimated $691K sold.
Based on aggregated 13F filings for Q2 2017.